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Target: aurora A kinase inhibitor
Mechanism of action:
It is selective and potent inhibitor of AAK. Aurora A directly binds to and regulates the turnover of N-myc, and is essential in N-myc amplified neuroblastomas. Also, Aurora A phosphorylate and regulate p53 function.
Hematologic: neutropenia, thrombocytopenia.
Gastrointestinal: diarrhea, nausea.
Dermatologic: alopecia.
Other: stomatitis, fatigue, somnolence.
[293] 
DRUGS UNDER TRIAL
Mechanism of action:
Inhibits serine/threonine protein phosphatase 2A and PP1-alpha. Causes apoptosis, inhibition of angiogenesis, and metastasis for many cell lines, and can affect multiple pathways controlling cell proliferation. Also, NCTD was found able to inhibit Pglycoprotein (P-gp) and overcome Multi drug resistance.
Other: Reduced cardiac and renal toxicity as compared to cantharidin.
[302] 
Inhibits the phosphorylation of signal transducer and activator of transcription 3 (STAT3), blocking the signaling pathways of interleukin-6 and vascular endothelial growth factor (VEGF) and downregulating the antiapoptotic proteins Bcl-2, Bcl-XL, and Mcl-1 inhibiting cell proliferation, inducing cell cycle arrest, and inducing apoptosis.
Hematologic: neutropenia.
Gastrointestinal: diarrhea, dyspepsia.
Other: liver enzyme elevation.
[ Hematologic: neutropenia, anemia.
Gastrointestinal: nausea, diarrhea.
Other: fatigue, increased AST, hypertension.
[310] Target: Protein kinase C beta (PKC-beta) inhibitor.
Mechanism of action:
Suppresses signaling through PKC-β and the phosphatidylinositol 3-kinase/AKT pathway to induce tumor cell apoptosis, reduce proliferation, and suppress tumor-induced angiogenesis.
Hematologic: anemia.
Gastrointestinal: diarrhea, vomiting.
Other: fatigue, dyspnea, hypotension, syncope.
[311] Gastrointestinal: nausea, vomiting, diarrhea.
Dermatologic: rash.
Other: fatigue, hyperglycemia.
[315] Gastrointestinal: diarrhoea, nausea, decreased appetite.
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Other: fatigue, insomnia.
[321] Hematologic: neutropenia, thrombocytopenia.
[322]
41 SNX-5422 SNX-2112.
Pfizer, N/A HSP90 inhibitor
Phase1 Trial
Target: HSP90 Mechanism of action: Disruption of Hsp90 function has been shown to cause degradation of multiple Hsp90 client proteins, leading to inhibition of several key signaling pathways. This in turn results in inhibition of cellular proliferation.
Gastrointestinal: nausea, emesis, diarrhea.
Other: fatigue.
[323] Hematologic: anemia, neutropenia.
Dermatologic: rash.
[324] Hematologic: anemia, thrombocytopenia.
Gastrointestinal: diarrhea, nausea, vomiting, constipation, abdominal pain, edema peripheral, abdominal distension.
Other: fatigue, cough, dizziness, insomnia, anorexia.
